ガイドライン

(旧版) 肝癌診療ガイドライン2009年版

書誌情報
 
文献検索式


MEDLINE(Dialog)

I.対象データ:2002年10月1日~2007年6月30日

疾患:肝細胞癌に限定(動物実験を除く)
言語:英語・日本語文献に限定

II.検索式

研究デザインによる絞込みのためのキーワード


【全CQ共通】
S1 DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES+PRACTICE GUIDELINES)/DF+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DF+PATIENT CARE PLANNING!+EVIDENCE-BASED MEDICINE/DF
S2 (CLINICAL+CRITICAL+TREATMENT?+CARE)(2N)(PATH+PATHS+PATHWAY?+PROTOCOL?+PLANNING?+GOOD(2W)PRACTICE?)/TI
S3 (SYSTEMATIC+QUANTITATIVE+METHODOLOGIC+COLLABORATIVE+INTEGRATIVE)(1W)(REVIEW?+OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACPJOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP TECHNOL ASSESS?)
S4 DT=META-ANALYSIS+META-ANALYSIS/DF+(META()ANALY?+METAANAL?)/TI
S5 DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DF+RANDOMALLOCATION/DF+RANDOM?+DOUBLE-BLIND METHOD/DF+SINGLE-BLIND METHOD/DF+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)
S6 DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DF+SINGLE-BLIND METHOD/DF+CROSS-OVER STUDIES/DF+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/ID+CONTROL?(1W)(TRIAL?+STUD?)+PLACEBO?/TI
S7 DT=CLINICAL TRIAL?+CLINICAL TRIALS!+(TRIAL?+STUDY+STUDIES)/TI
S8 COHORT STUDIES!+COHORT?/TI
S9 DT=MULTICENTER STUDY+MULTICENTER STUDIES/DF+(MULTICENT?+MULTI (W)CENT?)/TI
S10 CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS/DF+CASE()(CONTROL+COMPARISON?+REFERENT?+REFERRENT?)/TI+RETROSPECTIVE?/TI
S11 S1:S10

【予 防】
●CQ1 インターフェロン療法は,肝細胞癌の発癌予防に有効か?

S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 INTERFERONS!+INTERFERON?+INF+IFN
S18 PC/DE+PREVENTION?+PREVENTIVE?+PROPHYLAXIS?
S19 S16*S17*S18

●CQ2 肝庇護療法は肝細胞癌の発癌予防に有効か?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 (LIVER?+HEPAT?+HEPATOCELL?+HAEPATOCELL?)(1W)SUPPORT?+CHEMOPREVEN?+CHEMO(1W)PREVENT+SHO(1W)SAIKO(1W)TO+SHOSAIKOTO+XIAO(1W)CHAI (1W)HU(1W)TANG+TJ (1W)9+GLYCYRRHIZI?+URSODEOXYCHOLI?+STRONGER()NEO()MINOPHAGEN()C
S18 PC/DE+PREVENTION?+PREVENTIVE?+PROPHYLAXIS?
S19 S16*S17*S18

●CQ3 B型肝炎患者に対する核酸アナログ投与は肝細胞癌の発癌予防に有効か?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 HEPATITIS B!+HEPATITIS(2N)B+HEPATITISB
S18 ANTIVIRAL AGENTS!
S19 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S20 S16*S17*S18*S19

【診断およびサーベイランス】
●CQ4 定期的肝細胞癌スクリーニングは,どのような対象に行うべきか?

S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S11*S12
S14 S13/HUMAN OR(S13 NOT ANIMALS)
S15 S14/ENG
S16 S15 AND UP=20021001:20070630
S17 S15 AND UP=20070315:20070630
S18 S16+S17
S19 REGULAR? OR PERIODIC? OR ROUTINE? OR ANNUAL? OR SCHEDUL? OR CONSTANT?
S20 CHECK? OR SCREEN? OR EXAMIN? OR CONSULT? OR TEST? OR FOLLOW? OR SURVEILL?
S21 S19(3N)S20
S22 (SURVEILLANC?+SCREENING?)/TI
S23 S18*(S21+S22)
S24 RISK?(3N)(HIGH+FACTOR?+CASE+CASES+PATIENT+PATIENTS+SUBJECT+SUBJECTS)
S25 S24*S23

●CQ5 肝細胞癌の危険因子を有する症例に対する定期的スクリーニングは,肝細胞癌患者の予後を改善するか?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S11*S12
S14 S13/HUMAN OR(S13 NOT ANIMALS)
S15 S14/ENG
S16 S15 AND UP=20021001:20070630
S17 S15 AND UP=20070315:20070630
S18 S16+S17
S19 REGULAR? OR PERIODIC? OR ROUTINE? OR ANNUAL? OR SCHEDUL? OR CONSTANT?
S20 CHECK? OR SCREEN? OR EXAMIN? OR CONSULT? OR TEST? OR FOLLOW? OR SURVEILL?
S21 S19(3N)S20
S22 (SURVEILLANC?+SCREENING?)/TI
S23 S18*(S21+S22)
S24 PROGNOSIS!+PROGNOS?+SURVIV?(3N)(RATE+RATES+TIME?+CURVE?)+TUMOR(2N)(SIZE?+NUMBER?)+STAGE?+STAGING?+OUTCOME?
S25 (TREATMENT?+LATE?+LONG(1W)TERM)(2N)(CONSEQUENCE?+OUTCOME?+RESULT?)+RECURRENCE?+RELAPSE?+REOCCURRENCE?
S26 S23*(S24+S25)

●CQ6 肝細胞癌に対する定期的スクリーニングはどのように行うべきか?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S11*S12
S14 S13/HUMAN OR(S13 NOT ANIMALS)
S15 S14/ENG
S16 S15 AND UP=20021001:20070630
S17 S15 AND UP=20070315:20070630
S18 S16+S17
S19 REGULAR? OR PERIODIC? OR ROUTINE? OR ANNUAL? OR SCHEDUL? OR CONSTANT?
S20 CHECK? OR SCREEN? OR EXAMIN? OR CONSULT? OR TEST? OR FOLLOW? OR SURVEILL?
S21 S19(3N)S20
S22 (SURVEILLANC?+SCREENING?)/TI
S23 S18*(S21+S22)
S24 TUMOR MARKERS, BIOLOGICAL!+TUMOR?(3N)MARKER?+AFP+(ALFA+ALPHA)()FETOPROTEIN?+L3+PIVKA?+DCP+CT+TOMOGRA?+MRI+MAGNETIC?()RESONAN?+IMAGING?(3N)MODALIT?
S25 DIAGNOSTIC IMAGING!
S26 S23*(S24+S25)

●CQ7 肝細胞癌の診断において2種以上の腫瘍マーカーを測定することは有用か?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S18 (DI OR DIAGNOSIS! OR RA OR RI OR US)/DF OR DIAGNOS?/TI
S19 MULTI?+BI?+TWO?+COMBINAT?+COMBINE?+MIXED?+MIXUTER?
S20 TUMOR MARKERS, BIOLOGICAL!+MARKER?(2N)(TUMOR?+TUMOR?+CARCINO?+NEOPLASM?)+ALPHA(1W)FETOPROTEIN?+GAMMA(1W)CARBOXY(1W)PROTHROMBIN+PROTHROMBIN+PIVKA+AFP+DCP
S21 EVALUAT?+MEASURE?
S22 S16*S17*S18*S19*S20*S21

●CQ8 腫瘍マーカーの測定は,肝細胞癌の治療後の指標として有効か?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 TUMOR MARKERS, BIOLOGICAL!+MARKER?(2N)(TUMOR?+TUMOR?+CARCINO?+NEOPLASM?)+ALPHA(1W)FETOPROTEIN?+GAMMA(1W)CARBOXY(1W)PROTHROMBIN+PROTHROMBIN+PIVKA+AFP+DCP
S18 ACARBOXYPROTHROMBIN?+DESCARBOXYPROTHROMBIN?+(DESCARBOXYL?+ACARBOXY?)()PROTHROMBIN?
S19 “SENSITIVITY AND SPECIFICITY”!
S20 S16*(S17+S18)*S19

●CQ9 肝細胞癌の治療前検査としてどの画像診断を選択するか?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S18 PREEXAMINAT?+PRE(1W)EXAMINAT?+PREDIAGNOS?+PRETREATMENT?+PRETHERAP?+PRE(1W)(DIAGNO?+TREATMENT?+THERAP?)
S19 DIAGNOSTIC IMAGING!+IMAGE PROCESSING, COMPUTER-ASSISTED!+TOMOGRAPH?+IMAG?+ANGIOGRAPHY!+ARTERIOGRAPH?+ANGIOGRAPH?+AORTOGRAP?+ANGIOCARDIOPRAPH?+CINEANGIOGRAPH?+PHLEBOGRAPH?+PORTOGRAPH?+ULTRASONOGRAPHY!+ULTRASON?+ECHOGRAPH?+ECHO??+SONOGR?+ULTRASOUND?+ULTRASONICS!+US/DF+NUCLEAR(1W)MEDICINE(2N)DIAGNOSIS?+NUCLEAR MEDICINE!*DIAGNOSIS!+DIAGNOSTIC TECHNIQUES, RADIOISOTOPE!+HEADING RADIONUCLIDE IMAGING!+SCINT?+MRI+SPECT+PET+CT+(RA+RI)/DF
S20 S16*S17*S18*S19
S21 S17*S18*S19
S22 S21*UP=20021001:20070630
S23 S22/HUMAN OR(S21 NOT ANIMALS)
S24 S23/ENG

●CQ10 肝細胞癌の小結節の検出のために血管造影は必要か?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S18 (DI OR DIAGNOSIS! OR RA OR RI OR US)/DF OR DIAGNOS?/TI
S19 ANGIOGRAPHY!+ARTERIOGRAPH?+ANGIOGRAPH?+AORTOGRAP?+ANGIOCARDIOPRAPH?+CINEANGIOGRAPH?+PHLEBOGRAPH?+PORTOGRAPH?
S20 S16*S17*S18*S19

●CQ11 肝細胞癌の画像診断において造影剤使用は必要か,また,どのように造影剤を用いるべきか?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 DIAGNOSTIC IMAGING!+IMAGE PROCESSING, COMPUTER-ASSISTED!+TOMOGRAPH?+IMAG?+ANGIOGRAPHY!+ARTERIOGRAPH?+ANGIOGRAPH?+AORTOGRAP?+ANGIOCARDIOPRAPH?+CINEANGIOGRAPH?+PHLEBOGRAPH?+PORTOGRAPH?+ULTRASONOGRAPHY!+ULTRASON?
S18 ECHOGRAPH?+ECHO??+SONOGR?+ULTRASOUND?+ULTRASONICS!+US/DF+NUCLEAR(1W)MEDICINE(2N)DIAGNOSIS?+NUCLEAR MEDICINE!*DIAGNOSIS!+DIAGNOSTIC TECHNIQUES,RADIOISOTOPE!+HEADING RADIONUCLIDE IMAGING!+SCINT?+MRI+SPECT+PET+CT+(RA+RI)/DF
S19 CONTRAST MEDIA!+(CONTRAST+RADIOPAQUE)(1N)(MEDIA?+DYE?+MATERIAL?+AGENT?)
S20 S16*(S17+S18)*S19
S21 S20*(S17+S18)/TI
S22 S21*S19/TI
S23 S17/MAJ+S18/MAJ+S19/MAJ
S24 S23*S20
S25 S20*S19/TI
S26 (S17/MAJ+S18/MAJ)*S19/MAJ*S20
S27 S22*S26
S28 S22+S26

●CQ12 肝細胞癌の画像診断において,FDG-PET を含む核医学診断は他の検査法と比べて有用か?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 DIAGNOSTIC IMAGING!+IMAGE PROCESSING, COMPUTER-ASSISTED!+TOMOGRAPH?+IMAG?+ANGIOGRAPHY!+ARTERIOGRAPH?+ANGIOGRAPH?+AORTOGRAP?+ANGIOCARDIOPRAPH?+CINEANGIOGRAPH?+PHLEBOGRAPH?+PORTOGRAPH?+ULTRASONOGRAPHY!+ULTRASON?
S18 ECHOGRAPH?+ECHO??+SONOGR?+ULTRASOUND?+ULTRASONICS!+US/DF+NUCLEAR(1W)MEDICINE(2N)DIAGNOSIS?+NUCLEAR MEDICINE!*DIAGNOSIS!+DIAGNOSTIC TECHNIQUES,RADIOISOTOPE!+HEADING RADIONUCLIDE IMAGING!+SCINT?+MRI+SPECT+PET+CT+(RA+RI)/DF
S19 NUCLEAR(1W)MEDICINE(2N)DIAGNOSIS?+NUCLEAR MEDICINE!*DIAGNOSIS!+DIAGNOSTIC TECHNIQUES, RADIOISOTOPE!+HEADING RADIONUCLIDE IMAGING!!+SCINT?+MRI+SPECT+PET+CT+(RA+RI)/DF
S20 S16*(S17+S18)*S19
S21 S20*(S17+S18)/TI*S19/TI
S22 S21*S19/MAJ

●CQ13 肝細胞癌の確定診断のために針生検による組織診は必要か?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 (DI OR DIAGNOSIS! OR RA OR RI OR US)/DF OR DIAGNOS?/TI
S18 BIOPSY!+BIOPS?
S19 (ORGANIZATION?+TISSUE?)(1N)DIAGNOSIS?
S20 S16*S17*S18*S19
S21 S12*S18*S19
S22 S21/HUMAN+(S21 NOT ANIMALS)
S23 S22/ENG
S24 S23*UP=20021001:20051231+S23*UP=20060101:20070630
S25 S24*S16
S26 S24*S17
S27 S12*S17*S18
S28 S27*S16
S29 S28*S17/TI*S18/TI
S30 S28*S17/MAJ*S18/MAJ
S31 S29+S30
S32 S28 NOT S31

●CQ14 超音波造影剤は,肝細胞癌における超音波検査の診断能を改善するか?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 ULTRASONOGRAPHY!+ULTRASON?+ECHOGRAPH?+ECHO??+SONOGR?+ULTRASOUND?+ULTRASONICS!+US/DF
S18 CONTRAST MEDIA!+(CONTRAST+RADIOPAQUE)(1N)(MEDIA?+DYE?+MATERIAL?+AGENT?)/TI
S19 (DI OR DIAGNOSIS! OR RA OR RI OR US)/DF OR DIAGNOS?/TI
S20 S16*S17*S18*S19
S21 S20*S19/MAJ
S22 S21*S17/MAJ

●CQ15 造影超音波検査,RVS(real-time virtual sonography)は局所治療の治療ガイドとして有用か?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 ULTRASONOGRAPHY!+ULTRASON?+ECHOGRAPH?+ECHO??+SONOGR?+ULTRASOUND?+ULTRASONICS!+US/DF
S18 (CO2+CARBON(1N)DIOXIDE+CARBON DIOXIDE!)*((INJECTION?+INFUSION?)(1N)(INTRA(1W)ARTER?+INTRAARTER?)+INFUSIONS, INTRA-ARTERIAL!+INJECTIONS, INTRAARTERIAL!)
S19 RVS+(REALTIME+REAL)(1W)VIRTUAL?(1W)SONOGRAPH?
S20 PEI*(PERCUTANEOUS?+ETHANOL?)+PEIT+(PERCUTANEOUS?+TRANSDERMAL?)(2N)ETHANOL(2N)(INJECT?+INFUSION?)
S21 (LOCAL+TOPICAL)(3N)(REMED?+THERAP?+TREATMENT?)
S22 S16*(S17+S18+S19+S20)*S21

●CQ16 造影超音波検査は,TACEや局所療法の治療効果判定に有用か?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 ULTRASONOGRAPHY!+ULTRASON?+ECHOGRAPH?+ECHO??+SONOGR?+ULTRASOUND?+ULTRASONICS!+US/DF
S18 (ANTITHROMBOTIC+ANTI (1W)THROMBOTIC)(1W)REGIMEN?+EMBOLIZE?+(EMBOL?+THROMBUS?)(1N)FORM?+EMBOLIZATION, THERAPEUTIC!+TAE+TACE+((TRANSCATHETER?+TRANSARTER?+TRANS)(W)(CATHETER?+ARTER???))(3N)(EMBOLI?+CHEMOEMBOLI?)
S19 (LOCAL+TOPICAL)(3N)(REMED?+THERAP?+TREATMENT?)
S20 (BENEFIT?+EFFECT?+EFFIC?+GAIN?+PERFORMANCE?+ACTION?)(1N)(TREATMENT?+THERAP?+CURATIVE?)
S21 S16*S17*(S18+S19)*S20

【手 術】
●CQ17 肝切除術における最良の術前肝機能評価因子は?

S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 (HCC+LIVER+HEPAT?+NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)(3N)(RESECT? OR EXCIS? OR EXTIRPAT? OR ABLAT? OR TRANSECT? OR REMOV? OR ISOLAT? OR SURG? OR OPERAT? OR LAPARO? OR ENUCLEAT?)
S18 HEPATECTOM?
S19 S16 AND(S17 OR S18)
S20 PREOPERAT?+PRESURGER?+(BEFORE+PRE+PRIOR)(W)(OPERAT?+SURGER?+MASTECT?)+PREMASTECT?
S21 S20(3N)(ASSESSMENT? OR TEST??)
S22 S20 AND(HEPAT? OR LIVER)(3N)(FUNCTION? OR STATUS?)
S23 S19 AND(S21 OR S22)

●CQ18 非硬変肝細胞癌に対し,肝切除範囲はいかに決定すべきか?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 (HCC+LIVER+HEPAT?+NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)(3N)(RESECT?+EXCIS?+EXTIRPAT?+ABLAT?+TRANSECT?+REMOV?+ISOLAT?+SURG?+OPERAT?+LAPARO?+ENUCLEAT?)
S18 HEPATECTOM?
S19 S16 AND(S17+S18)
S20 NONCIRRHO?+NON(W)CIRRHO
S21 (WITHOUT+ABSEN?)(3W)CIRRHO?
S22 S19 AND(S20+S21)

●CQ19 再発肝細胞癌に対する有効な治療は?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 REAPPEARANC?+RECURREN?+REEMERGEN?+RELAPS?+REOCCURREN?
S18 S17(3N)(TREAT?+THERAP?+SURGER?+SURGIC?+RESECT?+OPERAT?+HEPATECTOM?+EFFECTIV?+RESPONSIV?)
S19 S17((4W)(INTRAHEPAT?+HEPATO?+HEPATI?+LIVER?+HCC+HCCS+DISEASE+DISEASES+CANCER?+TUMOR?+TUMOUR?+CARCINOM?+LESION?)
S20 (INTRAHEPAT?+HEPATO?+HEPATIC?+LIVER?+HCC+HCCS+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)(1W)S17
S21 TH/MAJ+SU/MAJ+DT/MAJ+RT/MAJ
S22 NEOPLASM RECURRENCE, LOCAL! (L)(TH+DT+RT+SU)
S23 S16*S18*(S19+S20)
S24 S16*(S19+S20)*S22
S25 S16*(S19+S20)*S21
S26 (S23+S24+S25)*(S18+S19+S20)/TI

●CQ20 肝切除後の予後因子は何か?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 (HCC+LIVER+HEPAT?)(3N)(RESECT? OR EXCIS? OR EXTIRPAT? OR ABLAT? OR TRANSECT? OR REMOV? OR ISOLAT? OR SURG? OR OPERAT? OR LAPARO? OR ENUCLEAT?)
S18 HEPATECTOM?
S19 S16 AND(S17 OR S18)
S20 (PREDICT? OR PROGNOS?)(N)(FACTOR? OR VARIABL?)
S21 S19 AND S20
S22 S21 AND CARCINOMA, HEPATOCELLULAR!/MAJ

●CQ21 切除断端距離は予後に寄与するか?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 (HCC+LIVER+HEPAT?)(3N)(RESECT? OR EXCIS? OR EXTIRPAT? OR ABLAT? OR TRANSECT? OR REMOV? OR ISOLAT? OR SURG? OR OPERAT? OR LAPARO? OR ENUCLEAT?)
S18 HEPATECTOM?
S19 S16 AND(S17 OR S18)
S20 SPECIM? OR SAMPL? OR TISSUE OR ORGANIZATION?
S21 PROGNOSIS!+PROGNOS?+(TREATMENT?+LATE?+LONG(1W)TERM)(2N)(CONSEQUENCE?+OUTCOME?+RESULT?)+SURVIVAL(1W)RATE?+RECURRENCE?+RELAPSE?+REOCCURRENCE?
S22 S19 AND S20 AND S21
S23 S22 AND CARCINOMA, HEPATOCELLULAR!/MAJ

●CQ22 系統的切除は予後に寄与するか?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 (ANATOMI?+SYSTEMIC?+SYSTEMATIC?)(4N)(RESECT?+HEPATECTOM?+SURGER?+SURGICA?+OPERATI?)
S18 PROGNOSIS!+PROGNOS?+CONSEQUENCE?+OUTCOME?+SURVIVAL?+RECURRENCE?+RELAPSE?+REOCCURRENCE?
S19 S16*S17*S18

●CQ23 周術期の血液製剤(赤血球輸血,凍結血漿など)使用はどうするか?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 SU/DF+SURGERY!+SURGICAL PROCEDURES, OPERATIVE!+SURGER???+OPERAT?+HEPATECTOMY!+HEPATECTOM?+(TUMOR?+TUMOUR?+CANCER?+CARCINOM?+LIVER?+HEPAT?)(3N)(RESECT?+REMOV?+ENUCLEAT?+EXTIRPAT?+EXCIS?+AMPUTAT?+ABLAT?)
S18 PERIPERAT?+INTRAOPERAT?+(PERI+INTRA+DURING?)(3N)(OP+SURGER???+OPERAT?+HEPATECTOM?+RESECT?)
S19 BLOOD TRANSFUSION! OR(BLOOD? OR ERYTHROCY? OR RED()CELL?? OR PLASMA?)(3N)TRANSFUS? OR FROZEN?(3N)PLASMA?
S20 BLOOD()(DERIVATIVE?+PREPARATION?+PRODUCT?+FORMUL?)+(HEMATOLOGIC?+HEMOPOIETIC?+HEMATOPOIETIC?)(2W)(DRUG??+AGENT??+FORMUL?)
S21 S16*S17*S18*(S19+S20)

●CQ24 肝切除術において術中出血量を減少させるにはどうするか?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 SU/DF+SURGERY!+SURGICAL PROCEDURES, OPERATIVE!+SURGER???+OPERAT?+HEPATECTOMY!+HEPATECTOM?+(TUMOR?+TUMOUR?+CANCER?+CARCINOM?+LIVER?+HEPAT?)(3N)(RESECT?+REMOV?+ENUCLEAT?+EXTIRPAT?+EXCIS?+AMPUTAT?+ABLAT?)
S18 BLOOD LOSS, SURGICAL!+BLOOD()LOSS?+(HEMORRHAGE?+BLEED?+HAEMORRHAG?)(3N)(OP+SURGIC?+SURGER???+OPERAT?+HEPATECTOM?+RESECT?+REMOV?+ENUCLEAT?+EXTIRPAT?+EXCIS?+AMPUTAT?+ABLAT?)
S19 S16*S17*S18

●CQ25 術前補助療法は肝切除後の予後を改善するか?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 SU/DF+SURGERY!+SURGICAL PROCEDURES, OPERATIVE!+SURGER???+OPERAT?+HEPATECTOMY!+HEPATECTOM?+POSTOPERAT?+POSTSURGER?+POSTHEPATECTOM?+(TUMOR?+TUMOUR?+CANCER?+CARCINOM?+LIVER?+HEPAT?)(3N)(RESECT?+REMOV?+ENUCLEAT?+EXTIRPAT?+EXCIS?+AMPUTAT?+ABLAT?)
S18 NEOADJUVANT?+NAC
S19 (PREOPERAT?+BEFORE(3N)(SURGER???+OPEARAT?+HEPATECTOM?+RESECT?))(4N)(CHEMOTHER?+THERAP?+TREAT?+ADMINIST?)
S20 CHEMOTHERAPY!+ANTINEOPLASTIC AGENTS! OR DT/DE+CHEMOTHERAP?+DRUG THERAPY!
S21 S16*S17*(S18+S19*S20)
S22 PROGNOSIS!+PROGNOS?+CONSEQUENCE?+OUTCOME?+SURVIVAL?+RECURRENCE?+RELAPSE?+REOCCURRENCE?
S23 S21*S22

●CQ26 術後補助療法は肝切除後の予後を改善するか?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 SU/DF+SURGERY!+SURGICAL PROCEDURES, OPERATIVE!+SURGER???+OPERAT?+HEPATECTOMY!+HEPATECTOM?+POSTOPERAT?+POSTSURGER?+POSTHEPATECTOM?+(TUMOR?+TUMOUR?+CANCER?+CARCINOM?+LIVER?+HEPAT?)(3N)(RESECT?+REMOV?+ENUCLEAT?+EXTIRPAT?+EXCIS?+AMPUTAT?+ABLAT?)
S18 CHEMOTHERAPY, ADJUVANT!+ADJUVANT?(3N)CHEMOTHER?
S19 (POSTOPERAT?+(AFTER+FOLLOW?)(3N)(SURGER???+OPEARAT?+HEPATECTOM?+RESECT?))(4N)(CHEMOTHER?+THERAP?+TREAT?+ADMINIST?)
S20 CHEMOTHERAPY!+ANTINEOPLASTIC AGENTS! OR DT/DE+CHEMOTHERAP?+DRUG THERAPY!
S21 S16*S17*(S18+S19*S20)
S22 PROGNOSIS!+PROGNOS?+CONSEQUENCE?+OUTCOME?+SURVIVAL?+RECURRENCE?+RELAPSE?+REOCCURRENCE?
S23 S21*S22

●CQ27 肝移植前の肝細胞癌に対する治療は予後を改善するか?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 PRETRANSPLAN?+PRE()TRANSPLAN?+(BEFORE+WAIT?)(3N)TRANSPLANT?
S18 (ANTITHROMBOTIC+ANTI (1W)THROMBOTIC)(1W)REGIMEN?+EMBOLIZE?+(EMBOL?+THROMBUS?)(1N)FORM?+EMBOLIZATION, THERAPEUTIC!+TAE+TACE+((TRANSCATHETER?+TRANSARTER?+TRANS)(W)(CATHETER?+ARTER???))(3N)(EMBOLI?+CHEMOEMBOLI?)
S19 EMBOLIZATION, THERAPEUTIC!
S20 TAE OR TACE OR(TRANSCATHETER? OR TRANSARTER?)(3N)(EMBOLI? OR CHEMOEMBOLI?)
S21 RFA+(RADIO(1W)(FREQUENC?+WAVE?)+RADIOFREQUEN?)(2N)ABLATION?
S22 (LOCAL?+LOCOREGION?+TOPICAL?)(3N)(THERAP?+TREAT?)
S23 ABLAT?
S24 BRIDG?(3W)(THERAP?+TREAT?)
S25 S16*S17*(S18+S19+S20+S21+S22+S23+S24)

●CQ28 肝移植後の予後因子は何か? またどのような腫瘍条件で肝移植が推奨されるか?(肝細胞癌移植候補患者の選択基準は何が適当か?)
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 LIVER TRANSPLANTATION! OR LIVER! (L)TR OR TRANSPLANT? OR DONAT? OR POSTTRANSPLANT?
S18 PROGNOSTI?(3N)FACTOR?
S19 S16*S17*S18
S20 (INDICAT?+ADAPT?+RECOMMEND?+SELECT?+CHOIC?+TARGET?+ELIGIBL?+CANDIDAT?+OFFER?)(4N)TRANSPLANT?
S21 S16*S17*S20

●CQ29 肝細胞癌症例のうち,手術適応,移植の適応となる症例,また手術と移植の双方が適応となる症例は,どの程度存在するのか? さらに双方の治療が可能となる症例ではどちらが良好な成績であるのか?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S11*S12
S14 S13/HUMAN OR(S13 NOT ANIMALS)
S15 S14/ENG
S16 S15 AND UP=20021001:20070630
S17 S15 AND UP=20070315:20070630
S18 S16+S17
S19 (INDICAT?+ADAPT?+RECOMMEND?+SELECT?+CHOIC?+TARGET?+ELIGIBL?+CANDIDAT?+OFFER?)(3N)(PATIENT+PATIENTS+SUBJECT+SUBJECTS+CASE+CASES)
S20 (EFFECTIV?+BENEFIT?)(3N)(PATIENT+PATIENTS+SUBJECT+SUBJECTS+CASE+CASES)
S21 (INDICAT?+ADAPT?+RECOMMEND?+SELECT?+CHOIC?+TARGET?+ELIGIBL?+CANDIDAT?+OFFER?)(4N)TRANSPLANT?
S22 (INDICAT?+ADAPT?+RECOMMEND?+SELECT?+CHOIC?+TARGET?+ELIGIBL?+CANDIDAT?+OFFER?)(4N)(RESECT?+HEPATECTOM?+OPERAT?+SURGER?)
S23 LIVER TRANSPLANTATION! OR LIVER! (L)TR OR TRANSPLANT? OR DONAT? OR POSTTRANSPLANT?
S24 SU/DF+SURGERY!+SURGICAL PROCEDURES, OPERATIVE!+SURGER???+OPERAT?+HEPATECTOMY!+HEPATECTOM?+POSTOPERAT?+POSTSURGER?+POSTHEPATECTOM?+(TUMOR?+TUMOUR?+CANCER?+CARCINOM?+LIVER?+HEPAT?)(3N)(RESECT?+REMOV?+ENUCLEAT?+EXTIRPAT?+EXCIS?+AMPUTAT?+ABLAT?)
S25 S18*(S19+S20)
S26 (S21+S23)*S25
S27 (S22+S24)*S25
S28 S26*S27+(INDICAT?+ADAPT?+RECOMMEND?+SELECT?+CHOIC?+TARGET?+ELIGIBL?+CANDIDAT?+OFFER?)(4N)BOTH(3N)TRANSPLANT?(4N)(RESECT?+HEPATECTOM?+OPERAT?+SURGER?)
S29 S28*S19:S22/TI
S30 (S26+S27)NOT S29
S31 S29*(S19:S22/TI+S19:S22/MAJ)
S32 S30*(S19:S22/TI+S19:S22/MAJ)
S33 (INDICAT?+ADAPT?+RECOMMEND?+SELECT?+CHOIC?+TARGET?+ELIGIBL?+CANDIDAT?+OFFER?)
S34 S29*S33/TI+S31
S35 S30*S33/TI+S32

●CQ30 背景肝疾患の相違(HBV, HCV, alcohol, PBC, cryptogenic)により移植後の成績に差はあるのか? また,適応は変わるのか?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S11*S12
S14 S13/HUMAN OR(S13 NOT ANIMALS)
S15 S14/ENG
S16 S15*UP=19820101:20000630
S17 S15*UP=20000701:20020630
S18 S15*UP=20030701:20050630
S19 S15*UP=20050701:20070630
S20 (S16+S17+S18+S19)AND PY>=1982
S21 LIVER TRANSPLANTATION! OR LIVER! (L)TR OR(LIVER? OR HEPATI?)(3N)(TRANSPLANT? OR DONAT?)
S22 S20*S21
S23 HEPATITI?+HBV+HCV+(HB+HC)()VIRU?+ALCOHOL?+PBC+PRIMARY(2W)BILIAR?(2N)CIRRHOS?+CRYPTOGENI?+BACKGROUND?
S24 S22*S23

【化学療法】
●CQ31 肝細胞癌化学療法はどのような症例に行われるか?

S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 DRUG THERAPY!+DT/DF+RADIOCHEM?+CHEMORADIO?+CHEMOTHERAP?+ANTINEOPLASTIC AGENTS!(L)(TU+AD)+CYCLOPHOSPHAMIDE?+FLUOROURACIL?+5(1W)FU+5FU+TEGAFUR?+UFT+CYTARABINE?+DOXORUBICIN?+ADRIAMYCIN?+EPIRUBICIN?+MITOXANTRONE?+MITOMYCIN?+CISPLATIN?
S18 S16*S17
S19 S17/TI AND S18
S20 DRUG THERAPY!+DT/DF+ANTINEOPLASTIC AGENTS! (L)(TU+AD)
S21 S18*S20
S22 S20/MAJ AND S21
S23 S22+S19

●CQ32 全身化学療法と比べて肝動注化学療法は有用か?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S11*S12
S14 S13/HUMAN OR(S13 NOT ANIMALS)
S15 S14/ENG
S16 S15*UP=20021001:20070630
S17 S15*UP=20070405:20070630
S18 S16+S17
S19 DRUG THERAPY!+DT/DF+RADIOCHEM?+CHEMORADIO?+CHEMOTHERAP?+ANTINEOPLASTIC AGENTS!(L)(TU+AD)+CYCLOPHOSPHAMIDE?+FLUOROURACIL?+5(1W)FU+5FU+TEGAFUR?+UFT+CYTARABINE?+DOXORUBICIN?+ADRIAMYCIN?+EPIRUBICIN?+MITOXANTRONE?+MITOMYCIN?+CISPLATIN?
S20 S18*S19
S21 HAI+(INTRAARTER?+ARTER?)(3N)(ADMINISTR?+DOSE?+DOSING?+INFUS?+INJECT?)
S22 (INTRAARTER? OR ARTER?)(3N)(THERAP? OR CHEMOTHERAP? OR TREAT?)
S23 (INTRAVENOUS?+VEIN?+VENOUS?)(3N)(ADMINISTR?+DOSE?+DOSING?+INFUS?+INJECT?)
S24 (SYSTEMIC?+INTRAVENOUS?)(3N)(CHEMOTHER?+THERAP?+TREAT?)
S25 S20*(S21+S22)*(S23+S24)

●CQ33 化学療法で有効な薬剤は何か?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 DRUG THERAPY!+DT/DF+RADIOCHEM?+CHEMORADIO?+CHEMOTHERAP?+ANTINEOPLASTIC AGENTS!(L)(TU+AD)+CYCLOPHOSPHAMIDE?+FLUOROURACIL?+5(1W)FU+5FU+TEGAFUR?+UFT+CYTARABINE?+DOXORUBICIN?+ADRIAMYCIN?+EPIRUBICIN?+MITOXANTRONE?+MITOMYCIN?+CISPLATIN?
S18 DRUG THERAPY!+DT/DF+ANTINEOPLASTIC AGENTS! (L)(TU+AD)
S19 S16*(S17/TI+S18/MAJ)
S20 S19*S12/TI

●CQ34 インターフェロン併用化学療法は有用か?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 DRUG THERAPY!+DT/DF+RADIOCHEM?+CHEMORADIO?+CHEMOTHERAP?+ANTINEOPLASTIC AGENTS!(L)(TU+AD)+CYCLOPHOSPHAMIDE?+FLUOROURACIL?+5(1W)FU+5FU+TEGAFUR?+UFT+CYTARABINE?+DOXORUBICIN?+ADRIAMYCIN?+EPIRUBICIN?+MITOXANTRONE?+MITOMYCIN?+CISPLATIN?
S18 INTERFERONS!+INTERFERON?+INF+IFN
S19 COMBIN?+CONCOMITANT?+DRUG THERAPY, COMBINATION!
S20 S16*S17*S18*S19

●CQ35 経口化学療法は効果があるのか?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S11*S12
S14 S13/HUMAN+(S13 NOT ANIMALS)
S15 S14/ENG
S16 S15*UP=20021001:20051231+S15*UP=20060101:20070630
S17 DRUG THERAPY!+DT/DF+RADIOCHEM?+CHEMORADIO?+CHEMOTHERAP?+ANTINEOPLASTIC AGENTS!(L)(TU+AD)+CYCLOPHOSPHAMIDE?+FLUOROURACIL?+5(1W)FU+5FU+TEGAFUR?+UFT+CYTARABINE?+DOXORUBICIN?+ADRIAMYCIN?+EPIRUBICIN?+MITOXANTRONE?+MITOMYCIN?+CISPLATIN?
S18 P()O+PER(1W)OS+ADMINISTRATION, ORAL!+(ORAL?+PERORAL?)(2N)ADMIN?+GIVE?(1W)MOUTH?
S19 S16*S17*S18
S20 S12*S17*S18/ENG
S21 S20/HUMAN+S20 NOT ANIMALS
S22 S21*UP=20021001:20051231+S21*UP=20060101:20070630

●CQ36 ホルモン療法は有効か?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S11*S12
S14 S13/HUMAN+(S13 NOT ANIMALS)
S15 S14/ENG
S16 S15*UP=20021001:20070630
S17 GONADOTROPIN-RELEASING HORMONE!+(LUTEINI?+GONADOTROPIN?)(3N)RELEAS?(2N)HORMON?(2N)(AGONIST?+ANALOG?)+LH(1W)RH+LHRH+GONADORELIN?+(GNRH+LHRH+(GN+LH)(1W)RH)(W)(AGONIST?+ANALOGUE?)+BUSERELIN?+GOSERELIN?+LEUPROLI?+NAFARELIN?+TRIPTORELIN?
S18 AROMATASE INHIBITORS!+AROMATAS?(2N)INHIBIT?+AMINOGLUTETHIMID?+TESTOLACTON?+FADROZOL?+ANASTROZOL?+LETROZOL?+EXEMESTAN?
S19 TAMOXIFEN?+ADOPAN+EMALOOK+SOSHIGEN+TASUOMIN+NORXIFEN+NOLVADEX+PANLEEF+PHENOLURN+RESPOL+ICI (1W)46474+ICI46474+ICI (1W)47699+ICI47699+ZITAZONIUM
S20 S17:S19
S21 S16*S20

●CQ37 化学療法の治療効果予測因子・予後因子は何か?
S12 CARCINOMA, HEPATOCELLULAR!+(HEPATOCELL?+HAEPATOCELL?+(HEPATO+HAEPATO))(W)(CELL??+CELLULA?)(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S11*S12
S14 S13/HUMAN OR(S13 NOT ANIMALS)
S15 S14/ENG
S16 S15*UP=20021001:20051231+S15*UP=20060101:20070630
S17 PREDICT?(1W)(FACTOR?+VARIABLE?)
S18 S16*S17
S19 (BENEFIT?+EFFECT?+EFFIC?+GAIN?+PERFORMANCE?+ACTION?)(1N)(TREATMENT?+THERAP?+CURATIVE?)
S20 S18*S19

●CQ38 肝内腫瘍に対する放射線治療は推奨されるか?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S11*S12
S14 S13/HUMAN OR(S13 NOT ANIMALS)
S15 S14/ENG
S16 S15 AND PY=>1982 AND UP=<20070630
S17 RADIOTHERAPY!+RT/DF+RADIOCHEM?+CHEMORADIO?+IRRADIAT?+RADIOTHERA?+RADIAT?+BRACHYTHER?
S18 S16*S17
S19 LIVER NEOPLASMS! (L)RT+CARCINOMA, HEPATOCELLULAR! (L)RT
S20 S18*S19
S21 (INTRAHEPATI?+LIVER?+HEPATIC?)(4N)(RT+RADIOCHEM?+CHEMORADIO?+IRRADIAT?+RADIOTHERA?+RADIAT?+BRACHYTHER?)
S22 S21/TI AND S20
S23 PRIMARY?(3N)(LIVER?+INTRAHEPATI?+HEPATIC?)+(TUMOR?+TUMOUR?+CARCINOM?+NEOPLASM?+CANCER?)(3N)(INTRAHEPATIC?+(IN+WITHIN)(3W)(LIVER?+HEPATIC?))
S24 (RECOMMEND?+INDICAT?+PREFER?)(4N)(RADIOTHER?+CHEMORADIO?+RADIOCHEM?+IRRADIAT?+RADIAT?+BRACHYTHER?)
S25 S20*S23
S26 S20*S24
S27 S22+S25+S26
S28 (IMPROV?+REDUCT?+LOWER?+DECREAS?+INCREAS?)(3N)(PROGNOSIS!+PROGNOS?+(TREATMENT?+LATE?+LONG(1W)TERM)(2N)(CONSEQUENCE?+OUTCOME?+RESULT?)+SURVIVAL(1W)RATE?+RECURRENCE?+RELAPSE?+REOCCURRENCE?)
S29 S18*S28
S30 (PROGNOSIS!+PROGNOS?/TI)AND S18
S31 (PROGNOSIS!/MAJ OR PROGNOS?/TI)AND S18
S32 S29+S31
S33 DISTAN?(4N)METASTA?
S34 S18*S33
S35 METASTA?(4N)(RADIOTHER?+CHEMORADIO?+RADIOCHEM?+IRRADIAT?+RADIAT?+BRACHYTHER?)
S36 S18*S35

●CQ39 放射線治療を行うことにより,予後は改善するか?
S12 CARCINOMA, HEPATOCELLULAR!+(HEPATOCELL?+HAEPATOCELL?+(HEPATO+HAEPATO))(W)(CELL??+CELLULA?)(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S11*S12
S14 S13/HUMAN OR(S13 NOT ANIMALS)
S15 S14/ENG
S16 S15 AND PY=>1982 AND UP=<20070630
S17 S15 AND PY=>1982 AND UP=19830906:20070630
S18 S15 AND PY=>1982 AND UP=19911105:20070630
S19 S15 AND PY=>1982 AND UP=19990708:20070630
S20 S15 AND PY=>1982 AND UP=20050211:20070630
S21 S16:S20
S22 RADIOTHERAPY!+RT/DF+RADIOCHEM?+CHEMORADIO?+IRRADIAT?+RADIOTHERA?+RADIAT?+BRACHYTHER?+RADIOSURGE?
S23 S21*S22
S24 PROGNOSIS!+PROGNOS?
S25 S23*S34
S26 OUTCOME?+SURVIV?+RECURRENCE?+RELAPSE?+REOCCURRENCE?
S27 S26*S23
S28 S25+S27

●CQ40 肝細胞癌の遠隔転移に対しては放射線治療が適応となるか?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S11*S12
S14 S13/HUMAN OR(S13 NOT ANIMALS)
S15 S14/ENG
S16 S15 AND PY=>1982 AND UP=<20070630
S17 S15 AND PY=>1982 AND UP=19830906:20070630
S18 S15 AND PY=>1982 AND UP=19911105:20070630
S19 S15 AND PY=>1982 AND UP=19990708:20070630
S20 S15 AND PY=>1982 AND UP=20050211:20070630
S21 S16:S20
S22 RADIOTHERAPY!+RT/DF+RADIOCHEM?+CHEMORADIO?+IRRADIAT?+RADIOTHERA?+RADIAT?+BRACHYTHER?+RADIOSURGE?
S23 S21*S22
S24 DISTAN?(4N)METASTA?
S25 S23*S24
S26 METASTA?(4N)(RADIOTHER?+CHEMORADIO?+RADIOCHEM?+IRRADIAT?+RADIAT?+BRACHYTHER?+RADIOSURG?)
S27 S23*S26
S28 DC=C4! (L)SECONDARY
S29 LIVER NEOPLASMS! (L)SECONDARY
S30 S23*(S28 NOT S29)
S31 NEOPLASM METASTASIS!
S32 S23*S31
S33 (LIVER?+HEPAT?)(4N)METASTA?
S34 SC/DE OR METASTA?
S35 S23*S34 NOT S33
S36 S25+S27+S30+S32+S35

【肝動脈化学塞栓療法(TACE)】
●CQ41 どのような症例がTACE/TAEのよい適応か?

S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 (ANTITHROMBOTIC+ANTI (1W)THROMBOTIC)(1W)REGIMEN?+EMBOLIZE?+(EMBOL?+THROMBUS?)(1N)FORM?+EMBOLIZATION, THERAPEUTIC!+TAE+TACE+((TRANSCATHETER?+TRANSARTER?+TRANSARTERIAL?+TRANS)(W)(CATHETER?+ARTER???+ARTERIAL?))(3N)(EMBOLI?+CHEMOEMBOLI?)
S18 (INDICAT?+ADPT?+RECOMMEND?+SELECT?+CHOIC?+TARGET?)(3N)(PATIENT+PATIENTS+SUBJECT+SUBJECTS+CASE+CASES)
S19 (EFFECTIV?+BENEFIT?)(3N)(PATIENT+PATIENTS+SUBJECT+SUBJECTS+CASE+CASES)
S20 INDICAT?/TI+INDICAT?(3N)(ETHANOL?+RFA+PEI+PMCT+ABLAT?)
S21 S16*S17*S18:S20

●CQ42 TACE/TAEに使用する塞栓物質は何を用いるべきか?
S1 DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES+PRACTICE GUIDELINES)/DF+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DF+PATIENT CARE PLANNING!+EVIDENCE-BASED MEDICINE/DF
S2 (CLINICAL+CRITICAL+TREATMENT?+CARE)(2N)(PATH+PATHS+PATHWAY?+PROTOCOL?+PLANNING?+GOOD(2W)PRACTICE?)/TI
S3 (SYSTEMATIC+QUANTITATIVE+METHODOLOGIC+COLLABORATIVE+INTEGRATIVE)(1W)(REVIEW?+OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP TECHNOL ASSESS?)
S4 DT=META-ANALYSIS+META-ANALYSIS/DF+(META()ANALY?+METAANAL?)/TI
S5 DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DF+RANDOM ALLOCATION/DF+RANDOM?+DOUBLE-BLIND METHOD/DF+SINGLE-BLIND METHOD/DF+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)
S6 DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DF+SINGLE-BLIND METHOD/DF+CROSS-OVER STUDIES/DF+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/ID+CONTROL?(1W)(TRIAL?+STUD?)+PLACEBO?/TI
S7 DT=CLINICAL TRIAL?+CLINICAL TRIALS!+(TRIAL?+STUDY+STUDIES)/TI
S8 COHORT STUDIES!+COHORT?/TI
S9 DT=MULTICENTER STUDY+MULTICENTER STUDIES/DF+(MULTICENT?+MULTI (W)CENT?)/TI
S10 CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS/DF+CASE()(CONTROL+COMPARISON?+REFERENT?+REFERRENT?)/TI+RETROSPECTIVE?/TI
S11 S1:S10
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 GELATIN? OR EMBOSPHERE?
S18 EMBOLIZ?(3N)(AGENT+AGENTS+DRUG+DRUGS+COMPOUND?+SUBSTANC?)
S19 PVA OR IVALON? OR POLYVINYL()(FOAM? OR SPONGE?)OR VINYL()ACETAL?()POLYMER?
S20 S16*(S17+S18+S19)

●CQ43 TACE/TAEで(化学)塞栓すべき脈管は?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S11*S12
S14 S13/HUMAN OR(S13 NOT ANIMALS)
S15 S14/ENG
S16 S15 AND UP=20021001:20070630
S17 S15 AND UP=20070315:20070630
S18 S16+S17
S19 GELATIN? OR EMBOSPHERE?
S20 EMBOLIZ?(3N)(AGENT+AGENTS+DRUG+DRUGS+COMPOUND?+SUBSTANC?)
S21 PVA OR IVALON? OR POLYVINYL()(FOAM? OR SPONGE?)OR VINYL()ACETAL?()POLYMER?
S22 S18*(S19+S20+S21)

●CQ44 肝動脈化学塞栓療法(TACE)にイオダイズドオイル(リピオドール)と抗癌剤のエマルジョン注入は必要か?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S11*S12
S14 S13/HUMAN OR(S13 NOT ANIMALS)
S15 S14/ENG
S16 S15 AND UP=20021001:20070630
S17 S15 AND UP=20070315:20070630
S18 S16+S17
S19 ANTINEOPLASTIC AGENTS! OR ANTI ()(CANCER? OR NEOPLASTIC? OR TUMOR? OR CARCINOM?)(()(AGENT?? OR DRUG??)OR CHEMOTHERAP?()(AGENT?? OR DRUG??)
S20 ETHIODIZE? OR IODIZE? OR IODOLIP? OR LIPIODOL? OR EMULSI?
S21 S19*S20
S22 TACL+CHEMOLIPIODOLI?
S23 S18*(S21+S22)

●CQ45 リピオドールと抗癌剤の混合液(リピオドールエマルジョン)に使用する抗癌剤は何が選択されるべきか?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S11*S12
S14 S13/HUMAN OR(S13 NOT ANIMALS)
S15 S14/ENG
S16 S15 AND UP=20021001:20070630
S17 S15 AND UP=20070315:20070630
S18 S16+S17
S19 LIPIODOL? OR IODOLIPOL? OR(ETHIODIZ? OR IODIZ?)()OIL?
S20 S19*S18
S21 INTRAVASC? OR HAI OR(INTRAHEPA? OR HEPATIC? OR LIVER?)(3N)ARTER?
S22 S20*S21
S23 (S19/TI OR S19/MAJ)AND S18
S24 S22+S23

●CQ46 再TACE/TAEの時期の選択は?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 (ANTITHROMBOTIC+ANTI (1W)THROMBOTIC)(1W)REGIMEN?+EMBOLIZE?+(EMBOL?+THROMBUS?)(1N)FORM?+EMBOLIZATION, THERAPEUTIC!+TAE+TACE+((TRANSCATHETER?+TRANSARTER?+TRANSARTERIAL?+TRANS)(W)(CATHETER?+ARTER???+ARTERIAL?))(3N)(EMBOLI?+CHEMOEMBOLI?)
S18 RETRI?+RE()TRI?+RETRY?+RE()TRY?+TRY()AGAIN?+REPERFORM?+RE()PERFORM?+ANOTHER?+REPEAT?+ADDITION?+SUPPLEMENT?+TWICE?+TWO()TIMES?+RETREATMENT?+RE()TREATMENT?+AGAIN?
S19 TIME?+TIMING?+PERIOD?+INTERVAL?+POINT?+OCCASION?
S20 S16*(S17*S18+RE()S17)*S19

●CQ47 TACE/TAEと他治療法の併用療法は有効か?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 (ANTITHROMBOTIC+ANTI (1W)THROMBOTIC)(1W)REGIMEN?+EMBOLIZE?+(EMBOL?+THROMBUS?)(1N)FORM?+EMBOLIZATION, THERAPEUTIC!+TAE+TACE+((TRANSCATHETER?+TRANSARTER?+TRANSARTERIAL?+TRANS)(W)(CATHETER?+ARTER???+ARTERIAL?))(3N)(EMBOLI?+CHEMOEMBOLI?)
S18 COMBINAT?+CONCOMITANT?+DRUG THERAPY, COMBINATION!+(TREATMENT?+THERAP?)(3N)(CONCURRENT?+PARALLEL?)
S19 S16*S17*S18

【穿刺局所療法】
●CQ48 穿刺局所療法はどのような患者に行うべきか?

S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S11*S12
S14 S13/HUMAN OR(S13 NOT ANIMALS)
S15 S14/ENG
S16 S15 AND UP=20021001:20070630
S17 S15 AND UP=20070315:20070630
S18 S16+S17
S19 ETHANOL/DE OR ETHANOL?(3N)(PERCUTAN? OR INJECT? OR INFUS? OR ADMINISTR? OR DOSE? OR DOSING?)
S20 (PEI OR PEIT OR EIT)AND ETHANOL??
S21 MICROWAVES/DE OR MICROWAVE?(3N)(PERCUTAN? OR COAGULAT?)
S22 (PMCT OR MCT)AND MICROWAVE?
S23 ELECTROCOAGULATION! OR RADIO WAVES/DE OR ABLAT?
S24 RADIOFREQUEN? OR RADIO()FREQUEN? OR RFA
S25 PEI*(PERCUTANEOUS?+ETHANOL?)+PEIT+(PERCUTANEOUS?+TRANSDERMAL?)(2N)(ETHANOL+ETHYL()ALCOHOL?)
S26 PMCT+PERCUTANEOUS?(1W)COAGULAT?(1W)THERAP?
S27 RFA+(RADIO(1W)(FREQUENC?+WAVE?)+RADIOFREQUEN?)(2N)ABLATION?
S28 S19:S27
S29 S28*S18
S30 (INDICAT?+ADPT?+RECOMMEND?+SELECT?+CHOIC?+TARGET?)(3N)(PATIENT+PATIENTS+SUBJECT+SUBJECTS+CASE+CASES)
S31 (EFFECTIV?+BENEFIT?)(3N)(PATIENT+PATIENTS+SUBJECT+SUBJECTS+CASE+CASES)
S32 INDICAT?/TI+INDICAT?(3N)(ETHANOL?+RFA+PEI+PMCT+ABLAT?)
S33 S29*(S30+S31+S32)

●CQ49 各穿刺局所療法の選択は,どのように行うべきか?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 (LOCAL+TOPICAL)(3N)(REMED?+THERAP?+TREATMENT?+CENTESIS+NEEDL?+NYXIS+PUNCTURE?+ACUPUNCTURE?)+(ETHANOL?+ALCOHOL?)(1W)INFUS?+RADIOFREQUEN?(1W)ABLAT?+RFA
S18 (ANTITHROMBOTIC+ANTI (1W)THROMBOTIC)(1W)REGIMEN?+EMBOLIZE?+(EMBOL?+THROMBUS?)(1N)FORM?+EMBOLIZATION, THERAPEUTIC!+TAE+TACE+((TRANSCATHETER?+TRANSARTER?+TRANS)(W)(CATHETER?+ARTER???))(3N)(EMBOLI?+CHEMOEMBOLI?)
S19 COMBIN?+CONCOMITANT?+DRUG THERAPY, COMBINATION!+DRGU COMBINATIONS!
S20 (IMPROV?+REDUCT?+LOWER?+DECREAS?+INCREAS?)(3N)(PROGNOSIS!+PROGNOS?+(TREATMENT?+LATE?+LONG(1W)TERM)(2N)(CONSEQUENCE?+OUTCOME?+RESULT?)+SURVIVAL(1W)RATE?+RECURRENCE?+RELAPSE?+REOCCURRENCE?)
S21 S16*S17*S18*S19*S20
S22 S16*S17*S18*S19

●CQ50 3cm超あるいは4個以上の肝細胞癌患者に対してTACEに穿刺局所療法を併用することは予後を改善するか?
S12 CARCINOMA, HEPATOCELLULAR!+(HEPATOCELL?+HAEPATOCELL?+(HEPATO+HAEPATO))(W)(CELL??+CELLULA?)(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S11*S12
S14 S13/HUMAN OR(S13 NOT ANIMALS)
S15 S14/ENG
S16 S15*UP=20021001:20051231+S15*UP=20060101:20070630
S17 (LOCAL+TOPICAL)(3N)(REMED?+THERAP?+TREATMENT?+CENTESIS+NEEDL?+NYXIS+PUNCTURE?+ACUPUNCTURE?)+(ETHANOL?+ALCOHOL?)(1W)INFUS?+RADIOFREQUEN?(1W)ABLAT?+RFA
S18 (ANTITHROMBOTIC+ANTI (1W)THROMBOTIC)(1W)REGIMEN?+EMBOLIZE?+(EMBOL?+THROMBUS?)(1N)FORM?+EMBOLIZATION, THERAPEUTIC!+TAE+TACE+((TRANSCATHETER?+TRANSARTER?+TRANS)(W)(CATHETER?+ARTER???))(3N)(EMBOLI?+CHEMOEMBOLI?)
S19 COMBIN?+CONCOMITANT?+DRUG THERAPY, COMBINATION!
S20 (IMPROV?+REDUCT?+LOWER?+DECREAS?+INCREAS?)(3N)(PROGNOSIS!+PROGNOS?+(TREATMENT?+LATE?+LONG(1W)TERM)(2N)(CONSEQUENCE?+OUTCOME?+RESULT?)+SURVIVAL(1W)RATE?+RECURRENCE?+RELAPSE?+REOCCURRENCE?)
S21 S16*S17*S18*S19

●CQ51 血流遮断下RFAは,予後を改善するか?
S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA??)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13 S12/HUMAN+(S12 NOT ANIMALS)
S14 S13/ENG
S15 S14*UP=20021001:20051231+S14*UP=20060101:20070630
S16 S11*S15
S17 (ANTITHROMBOTIC+ANTI (1W)THROMBOTIC)(1W)REGIMEN?+EMBOLIZE?+(EMBOL?+THROMBUS?)(1N)FORM?+EMBOLIZATION, THERAPEUTIC!+TAE+TACE+((TRANSCATHETER?+TRANSARTER?+TRANS)(W)(CATHETER?+ARTER???))(3N)(EMBOLI?+CHEMOEMBOLI?)
S18 (BLOOD?(2N)(CURRENT?+FLOW?+STREAK?+STREAM?+SUPPLY?)+BLOODSTREAM?+INFLOW?+VASCULAR?+ARTER?+AORTIC?)(3N)(BLOCK?+INHIBIT?+INTERRUPT?+OCCLUSION?+SHUTDOWN?+LIGATION?+STOP?)+ANTI (1W)VASCULAR?+ANTIVASCULAR?
S19 RFA+(RADIO(1W)(FREQUENC?+WAVE?)+RADIOFREQUEN?)(2N)ABLATION?
S20 PROGNOSIS!+PROGNOS?+(TREATMENT?+LATE?+LONG(1W)TERM)(2N)(CONSEQUENCE?+OUTCOME?+RESULT?)+SURVIVAL(1W)RATE?+RECURRENCE?+RELAPSE?+REOCCURRENCE?
S21 S16*S17*S18*S19*S20

 

書誌情報